Physician profile
Danlu Wang
NPI 1881011773
$4,049.86
in general payments reported to CMS, 2019-2025
18 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $265 · 2021: $477 · 2022: $281 · 2023: $393 · 2024: $657 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,442.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $676.33 | 2020-2025 | Entyvio |
| Gilead Sciences, INC. | $533.02 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.79 | 2020-2023 | Xifaxan |
| Janssen Biotech, INC. | $208.67 | 2020-2024 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $143.49 | 2025 | Tremfya |
| Genzyme Corporation | $137.11 | 2024 | |
| Intercept Pharmaceuticals, INC. | $112.30 | 2021-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $104.37 | 2024-2025 | Iqirvo |
| Abbvie INC. | $90.89 | 2020-2025 | |
| Pfizer INC. | $60.00 | 2023-2024 | |
| Medtronic, INC. | $46.17 | 2024 | Bravo |
| Ardelyx, INC. | $41.12 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $38.48 | 2022-2023 | Rebyota |
| Madrigal Pharmaceuticals | $32.14 | 2024 | Resmetirom |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $28.81 | 2023 | Terlivaz |
| Napo Pharmaceuticals INC | $21.48 | 2025 | Mytesi |
| Braintree Laboratories, INC. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danlu Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.